UBS Maintains Buy on AtriCure, Lowers Price Target to $50

Benzinga Newsdesk www.benzinga.com Negative 48.7%

Neg 48.7% Neu 0% Pos 0%

UBS analyst Priya Sachdeva maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $55 to $50.

Comments

No comments yet. Be the first!